Table 2.
Effect of endometriosis and menstrual cycle phase on expression of prostaglandin receptors and transporters in endometrium, based on real-time PCR and normalized relative to GAPDH mRNA as mean % ± SD. Also, n = 30, 50, and 28, respectively, for healthy (control) subjects, eutopic tissue samples from endometriosis patients, and ectopic tissue samples.
| Gene |
Controls (mean ± SEM) |
Endometriosis | |
|---|---|---|---|
| Eutopic (mean ± SEM) |
Ectopic (mean ± SEM) |
||
| EP1 | |||
| Proliferative phase | 317,2 ± 100,5 | 307,0 ± 42,13 | 307,3 ± 54,11 |
| Secretory phase | 209,5 ± 35,33 | 200,2 ± 37,57 | 411,3 ± 128,9 |
|
| |||
| EP2 | |||
| Proliferative phase | 57,90 ± 17,46 | 66,60 ± 22,24 | 71,74 ± 14,89 |
| Secretory phase | 198,2 ± 51,72† | 179,5 ± 38,82† | 112,6 ± 17,9 |
|
| |||
| EP3 | |||
| Proliferative phase | 28,55 ± 6,652 | 29,76 ± 3,444 | 1021 ± 249,3∗∗∗+++ |
| Secretory phase | 73,94 ± 20,06† | 48,35 ± 6,463†† | 1310 ± 276,1∗∗∗+++ |
|
| |||
| EP4 | |||
| Proliferative phase | 34,38 ± 12,67 | 46,82 ± 22,68 | 380,2 ± 136,5∗∗∗+ |
| Secretory phase | 21,94 ± 6,654 | 10,47 ± 1,546 | 583,4 ± 205,2∗∗∗+++ |
|
| |||
| FP | |||
| Proliferative phase | 237,5 ± 31,18 | 1059 ± 497,2 | 9213 ± 1947∗∗∗+++ |
| Secretory phase | 97,27 ± 18,26†† | 229,6 ± 61,22†† | 14268 ± 2742∗∗∗+++ |
|
| |||
| PGT | |||
| Proliferative phase | 16,04 ± 4,058 | 21,74 ± 3,682 | 56,42 ± 14,73∗∗+ |
| Secretory phase | 5,964 ± 3,326†† | 6,760 ± 2,736††† | 88,69 ± 25,28∗∗∗+++ |
|
| |||
| MRP4 total | |||
| Proliferative phase | 142,9 ± 63,47 | 97,05 ± 15,51 | 591,5 ± 227∗∗+ |
| Secretory phase | 80,93 ± 16,17 | 154,7 ± 25,77 | 931,2 ± 386,5∗∗∗+++ |
|
| |||
| MRP4 variant 1 | |||
| Proliferative phase | 160,9 ± 15,28 | 157,8 ± 18,82 | 194,2 ± 24,08 |
| Secretory phase | 196,2 ± 24,35 | 178,8 ± 18,99 | 164,7 ± 20,93 |
Note: ** P < 0.01 and *** P < 0.001 versus the control group; + P < 0.05 and +++ P < 0.001 versus the eutopic group; † P < 0.05 and †† P < 0.01 versus expression in the corresponding proliferative phase; ††† P < 0.001.